Cornea Biosciences

Executive Summary

Cornea Biosciences, a San Diego-based private biotech founded in 2018, is pioneering regenerative therapies and diagnostics for corneal diseases. Leveraging tissue engineering, the company aims to address significant unmet needs in ophthalmology, particularly for conditions that lead to vision loss. While still in early stages with no disclosed funding or clinical pipeline, its focus on restoring vision through innovative approaches positions it as a potential disruptor. The company's progress hinges on advancing its preclinical programs toward first-in-human studies and securing strategic partnerships or funding.

Upcoming Catalysts (preview)

• Q4 2026Initiation of first-in-human clinical trial for lead tissue-engineered corneal graft40% success
• Q3 2026Publication of preclinical efficacy data in peer-reviewed journal60% success
• Q4 2026Series A funding round announcement50% success